Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Pa Shun International Holdings Limited ( (HK:0574) ) has issued an announcement.
Pa Shun International Holdings Limited has warned shareholders and investors that it expects to report a widened net loss of between RMB20 million and RMB27 million for the year ended 31 December 2025, compared with a net loss of RMB15.3 million a year earlier. The larger loss stems mainly from the inclusion of many of the group’s products in China’s National Centralised Drug Procurement programme in 2025, which forced price cuts and sharply compressed gross profit margins.
The company said its 2025 figures are based on preliminary unaudited management accounts and remain subject to adjustments and review by the board and audit committee. It plans to release full annual results around 31 March 2026 and cautioned shareholders and potential investors to exercise care when dealing in its securities, underscoring the pressure that state-driven price reforms are exerting on pharmaceutical margins.
The most recent analyst rating on (HK:0574) stock is a Hold with a HK$0.06 price target. To see the full list of analyst forecasts on Pa Shun International Holdings Limited stock, see the HK:0574 Stock Forecast page.
More about Pa Shun International Holdings Limited
Pa Shun International Holdings Limited is a Cayman Islands-incorporated company listed in Hong Kong, operating in the pharmaceutical sector. The group focuses on the production and sale of drug products in mainland China, where a significant portion of its portfolio is subject to national drug procurement and pricing policies aimed at reducing medical costs.
Average Trading Volume: 1,390,296
Technical Sentiment Signal: Sell
Current Market Cap: HK$59M
For an in-depth examination of 0574 stock, go to TipRanks’ Overview page.